title: Pharmacokinetics of 9alpha-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate.
abstract: Medroxyprogesterone acetate (MPA) is widely used in endocrine therapy for breast cancer and other diseases. Recently, it has been demonstrated that 9alpha-fluoromedroxyprogesterone acetate (FMPA) also has anti-tumour activity in chemical-induced rat mammary tumour and its activity is greater than that of MPA. In the present study, the physico-chemical properties of FMPA and MPA and their pharmacokinetics in female rats were investigated. Partition coefficients (log P) of FMPA and MPA were 3.1 and 3.8, respectively, while the solubilities of FMPA and MPA in phosphate buffer saline were 3.8 and 1.1 microg/mL, respectively. When the two agents were intravenously or orally administered into female rats, there was no significant difference between their plasma concentrations. However, unmetabolized drug excreted into urine accounted for 4.7 and 0.7% of the intravenous dose of FMPA and MPA, respectively. The free fraction of FMPA in rat plasma was approximately four times that of MPA. Assuming the well-stirred model, hepatic intrinsic clearances of FMPA and MPA were estimated to be 64 and 293 L/h per kg, respectively. In addition, the free fraction of FMPA in blood is estimated to be higher than that of MPA, which may explain the higher anti-tumour activity.
authors.affiliation: Department of Pharmaceutical Development, Meiji Institute of Health Science, Meiji Milk Products Company, Limited, Odawara, Kanagawa, Japan.
authors.forename: D
authors.initials: D
authors.lastname: Kozutsumi
authors.forename: A
authors.initials: A
authors.lastname: Kawashima
authors.forename: T
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kotohda
authors.forename: S
authors.initials: S
authors.lastname: Fujimori
authors.forename: M
authors.initials: M
authors.lastname: Takami
authors.forename: T
authors.initials: T
authors.lastname: Kohno
authors.forename: T
authors.initials: T
authors.lastname: Oikawa
authors.forename: E
authors.initials: E
authors.lastname: Sugino
authors.forename: T
authors.initials: T
authors.lastname: Choshi
authors.forename: S
authors.initials: S
authors.lastname: Hibino
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate; D011374:Progesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: C105228:17-acetoxy-9-fluoro-6-methylprogesterone; D000970:Antineoplastic Agents; D045167:Progesterone Congeners; D011374:Progesterone; D008525:Medroxyprogesterone